Roche (SIX:RO,ROG; OTCQX:RHHBY) announced that it received FDA approval for the intravenous (IV) monoclonal antibody Actemra (tocilizumab) for hospitalized patients with severe COVID-19. The indication covers hospitalized adults receiving systemic corticosteroids who need supplemental oxygen, noninvasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). Tocilizumab targets the interleukin-6 receptor. It first won FDA approval…